CMTS0929

Phase 1Biologic

TThe Second Hospital of Nanjing Medical University

CMTS0929 is one of 50 biologic programs targeting Inflammatory Bowel Disease. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Inflammatory Bowel DiseaseActive, not recruiting

Clostridioides Difficile InfectionActive, not recruiting

Inflammatory Bowel DiseasePhase 1

Active, not recruiting

Clostridioides Difficile InfectionPhase 1

Active, not recruiting

Competition

Competitive Landscape

151 competitors in Inflammatory Bowel Disease

#DrugCompanyPhaseTrials

Remicade

OOrganon and Co

Phase 3

17 2

Stelara

Johnson & Johnson

Phase 3

1 3

Thalomid

Bristol-Myers Squibb

Phase 3

1 4

Farxiga

AstraZeneca

Phase 3

1 5

Humira

CCelltrion

Phase 3

7 6

Omvoh

Eli Lilly

Phase 3

—7

Valcyte

EEngelhard Arzneimittel GmbH & Co.KG

Phase 3

1 8

Deltavit

HHyundai Pharmaceutical Co., LTD.

Phase 3

—9

Iron Sulphate

PPierre Fabre Pharma GmbH

Phase 3

2 10

Sucrosomial Iron

CCardiochirurgia E.H.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2030

Phase 1Not yet recruiting

Clostridioides Difficile Infection

NCT06836427

Phase 1Not yet recruiting

Inflammatory Bowel Disease

NCT06844708

Clinical

Trials by Indication[1]

Clostridioides difficile Infection1 trial

CMTS0929 for Clostridioides Difficile Infection

Not yet recruiting·TThe Second Hospital of Nanjing Medical University·Phase 1·NCT06836427·12 enrolled

Inflammatory Bowel Disease1 trial

CMTS0929 for Inflammatory Bowel Disease

Not yet recruiting·TThe Second Hospital of Nanjing Medical University·Phase 1·NCT06844708·12 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for CMTS0929. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CMTS0929 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CMTS0929. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — The Second Hospital of Nanjing Medical University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: TThe Second Hospital of Nanjing Medical University

CMTS0929

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2030

Trials by Indication[1]

Clostridioides difficile Infection1 trial

Inflammatory Bowel Disease1 trial

References

Drug Info

Quick Facts

Related News